Is Global Blood Therapeutics Inc (GBT)’s Fuel For Real? The Stock Just Increased Again

August 2, 2017 - By reb123z

The stock of Global Blood Therapeutics Inc (NASDAQ:GBT) is a huge mover today! About 629,884 shares traded. Global Blood Therapeutics Inc (NASDAQ:GBT) has risen 43.51% since August 2, 2016 and is uptrending. It has outperformed by 26.81% the S&P500.
The move comes after 6 months positive chart setup for the $1.17B company. It was reported on Aug, 2 by Barchart.com. We have $27.82 PT which if reached, will make NASDAQ:GBT worth $46.80M more.

Analysts expect Global Blood Therapeutics Inc (NASDAQ:GBT) to report $-0.60 EPS on August, 9.They anticipate $0.02 EPS change or 3.45 % from last quarter’s $-0.58 EPS. After having $-0.60 EPS previously, Global Blood Therapeutics Inc’s analysts see 0.00 % EPS growth.

Global Blood Therapeutics Inc (NASDAQ:GBT) Ratings Coverage

Among 5 analysts covering Global Blood Therapeutics (NASDAQ:GBT), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Global Blood Therapeutics had 8 analyst reports since September 8, 2015 according to SRatingsIntel. The company was initiated on Tuesday, September 8 by Morgan Stanley. The stock has “Outperform” rating by Wedbush on Tuesday, October 25. The rating was initiated by JP Morgan with “Overweight” on Wednesday, January 4. The stock of Global Blood Therapeutics Inc (NASDAQ:GBT) earned “Buy” rating by Empire on Friday, June 17. As per Tuesday, September 8, the company rating was initiated by Wedbush. Goldman Sachs initiated Global Blood Therapeutics Inc (NASDAQ:GBT) rating on Tuesday, September 8. Goldman Sachs has “Neutral” rating and $44.0 target. Cowen & Co initiated it with “Outperform” rating and $80 target in Tuesday, September 8 report.

More notable recent Global Blood Therapeutics Inc (NASDAQ:GBT) news were published by: Nasdaq.com which released: “Implied Volatility Surging for Global Blood Therapeutics (GBT) Stock Options” on July 03, 2017, also Seekingalpha.com with their article: “Global Blood Therapeutics Continues To Be An Attractive Run-Up Play” published on July 06, 2017, Thestreet.com published: “Global Blood Therapeutics Shares Jump on Report It Was Approached by Novo Nordisk” on March 08, 2017. More interesting news about Global Blood Therapeutics Inc (NASDAQ:GBT) were released by: Globenewswire.com and their article: “Global Blood Therapeutics Expands Ongoing Phase 2a HOPE-KIDS 1 Study into …” published on July 10, 2017 as well as Globenewswire.com‘s news article titled: “Global Blood Therapeutics Prices a $125.0 Million Upsized Common Stock Public …” with publication date: February 22, 2017.

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $1.17 billion. The Firm is engaged in discovering, developing and commercializing therapeutics to treat blood disorders. It currently has negative earnings. The Firm is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease .

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: